🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🫧 Huge congrats to Dr. Oyepeju Abioye-Akintola Oyepeju Abioye-Akintola, MD, MSc on a stellar #ASCO25 poster presentation! Her study, “The Bubble Effect,” 🫧 asked bold questions on the power of #SoMe in oncology—and delivered data to match 📲📈 📚 Key takeaways: 🔹 ASCO tweets and Journal of Clinical Oncology

Huge congrats to my friend, Hem-Onc Fellows Network , & fellow ASCO TECAG member Dr. Fionnuala Crowley (Fionnuala Crowley) on her #ASCO25 poster addressing a critical question in trial equity & supportive care: Can we integrate palliative care earlier for patients in early-phase clinical

Congrats to Dr. Tracy Rose on presenting results from LCCC1827, a neoadjuvant trial of pembrolizumab ± entinostat in cis-ineligible #MIBC at #ASCO25 🦠🧬 🔍 Key findings in 20 patients: — ✅ pCR: 29%, pRR: 43% in both arms (P vs P+Ent) — ✅ cT0 on TMT: 100% in P alone, 66% with

Incredible work by incoming H.O.M.E Duaa Kanan, MD at #ASCO25! 🧠🧬 Her poster highlights a structure-based AI pipeline for identifying novel #NSCLC therapies via FDA-approved & investigational drug repurposing. ✅ Target: USP21, implicated in chemo resistance 🧪 Screened

🏆 Big congrats to UNC Lineberger on winning the 2025 City of Hope Healio Clinical Innovation Award at #ASCO25 for their game-changing at-home symptom reporting platform! Led by Ethan Basch & team Ashley Leak Bryant PhD, RN, OCN, FAAN , this digital tool: ✅ Reduced ER visits ✅ Boosted QoL ✅

A big congrats to my friend and fellow Hem-Onc Fellows Network at Yale Hematology Oncology Fellows Philippos Apolinario Costa, MD on his ASCO25 poster evaluating olaparib in IDH1/2-mutant chondrosarcomas and solid tumors 🧬📉 Though the results were negative, they speak volumes: 🔹 ORR: 0% 🔹 mPFS: 2.0 mo 🔹 mOS: 4.6 mo 🔹

🚨 First-in-human trial alert from #ASCO25! 🧬🧪 Shoutout to my fellow ASCO TECAG member Fionnuala Crowley for presenting the TPS2696 poster on combining anti–IL-4Rα (dupilumab) with anti–PD-1 (cemiplimab) in resectable early-stage #NSCLC 👏 🔹 Targeting IL-4 signaling—a novel

📣 Powerful work by @YabdouMD at #ASCO25 exposing a critical reality: eligibility alone isn’t equity. In this real-world study, Black women with HR+/HER2− early breast cancer—eligible for ribociclib per NATALEE—still faced worse RFS, DRFS, and OS compared to White women. ⚖️

Important early data from Dr. Anuja Abhyankar Anuja Abhyankar at #ASCO25 🧪🧠 In this single-center cohort study, prophylactic dexamethasone use in CAR T-cell recipients with elevated ferritin/CRP was associated with: 🔻 Lower rates of ≥Grade 3 CRS 🔼 Higher CR (60% vs 30%) 🟣

Absolutely 👏 phenomenal work by Nikita Baclig at #ASCO25 highlighting how the fall of Roe v. Wade is reshaping oncofertility care 🧬⚖️ 💥 62.5% of National Comprehensive Cancer Network (NCCN) centers reported an ⬆️ in cancer patients pursuing fertility preservation 📉 Yet response rates from states with restricted

📢 The 🟰 #EQUAL study presented at #ASCO25 by #FlorezLab is redefining who gets screened for lung 🫁 cancer. Using blood-based EGFR ctDNA testing in Latinx & East/Southeast Asian 🌏 nonsmokers, this trial is paving a path toward equity in early detection. 🧬🩸 🧪 Over 60% of

Thrilled to officially join the 2025–2026 ASCO Trainee & Early Career Advisory Group (ASCO TECAG )! 💼🌟 This powerhouse team brings together trainees from across the country united by a shared mission: championing the next generation of oncologists. Grateful for the

Huge congratulations to Joshua Zeidner MD on a stellar European Hematology Association presentation + first-author Journal of Clinical Oncology publication! The Aza/Ven/Revumenib triplet in newly diagnosed older/unfit NPM1m or KMT2Ar #AML delivered: 🧬 ORR 88% | CRc 81% | CR 67% 🔬 100% MRD-negative by flow 🚫 0%